Last reviewed · How we verify

oxybutynin immediate release — Competitive Intelligence Brief

oxybutynin immediate release (oxybutynin immediate release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic. Area: Urology.

marketed Anticholinergic Muscarinic acetylcholine receptors (M2 and M3) Urology Small molecule Live · refreshed every 30 min

Target snapshot

oxybutynin immediate release (oxybutynin immediate release) — Astellas Pharma Inc. Oxybutynin is an anticholinergic that blocks muscarinic receptors in the bladder, leading to relaxation of the detrusor muscle and increased bladder capacity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
oxybutynin immediate release TARGET oxybutynin immediate release Astellas Pharma Inc marketed Anticholinergic Muscarinic acetylcholine receptors (M2 and M3)
Yupelri REVEFENACIN Mylan Ireland Ltd marketed Anticholinergic [EPC] Muscarinic acetylcholine receptor M3 2018-01-01
Incruse Ellipta UMECLIDINIUM Glaxo Grp England marketed Anticholinergic Muscarinic acetylcholine receptor M4 2013-01-01
Tudorza Pressair ACLIDINIUM BROMIDE Covis marketed Anticholinergic M3 receptors, beta 2 -adrenergic receptors 2012-01-01
Spiriva TIOTROPIUM BROMIDE Boehringer Ingelheim marketed Anticholinergic Muscarinic acetylcholine receptor M3 2004-01-01
Atrovent IPRATROPIUM marketed Anticholinergic Muscarinic acetylcholine receptor M1 1986-01-01
Librax CLIDINIUM Roche marketed Anticholinergic Muscarinic acetylcholine receptor M3 1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic class)

  1. · 4 drugs in this class
  2. Pearl Therapeutics, Inc. · 3 drugs in this class
  3. Shionogi · 2 drugs in this class
  4. Ain Shams University · 1 drug in this class
  5. Astellas Pharma Inc · 1 drug in this class
  6. Boehringer Ingelheim · 1 drug in this class
  7. Covis · 1 drug in this class
  8. Forest Labs Inc · 1 drug in this class
  9. Fougera Pharms · 1 drug in this class
  10. Glaxo Grp England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxybutynin immediate release — Competitive Intelligence Brief. https://druglandscape.com/ci/oxybutynin-immediate-release. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing